CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

orteronel

Small moleculeexperimental

Orteronel (TAK-700) is a nonsteroidal CYP17A1 inhibitor that was being developed for the treatment of cancer by Takeda Pharmaceutical Company in conjunction with Millennium Pharmaceuticals. It completed two phase III clinical trials for metastatic, hormone-refractory prostate cancer but failed to extend overall survival rates, and development was voluntarily terminated as a result. — Wikipedia

Clinical trial activity

19 trials · 28 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
18
Phase 3
6
Phase 4
0

Earliest trial started Apr 1, 2008 (NCT00569153)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1
Mol. weight
307.35 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 6-((7s)-7-hydroxy-6,7-dihydro-5h-pyrrolo(1,2-c)imidazol-7-yl)-n-methyl-2-naphthamide
  • orteronel
  • orteronel
  • orteronel
  • orteronel
  • orteronel
  • orteronel, (r)-
  • tak-700
  • tak-700
  • tak-700
  • tak-700

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02101684Phase 2Jun 1, 2014Clinica Universidad de Navarra, Grupo Español de Tumores Huérfanos e Infrecuentes, Hospital Son Llatzer, Hospital Universitario Fundación Alcorcón, Hospital Universitario Madrid Sanchinarro, Takeda, Universidad Autonoma de Barcelona, Universidad Autonoma de Madrid, Universitario de Santiago, Spain, University of Valencia
NCT02054793Phase 1/Phase 2 (Phase 2)Jun 1, 2014Johns Hopkins University, Millennium Pharmaceuticals
NCT02053311Phase 3Jun 1, 2014Cantonal Hospital of St. Gallen, Kantonsspital Graubünden, Swiss Group for Clinical Cancer Research
NCT01990209Phase 2Mar 1, 2014Millennium Pharmaceuticals, SCRI Development Innovations
NCT01658527Phase 2Jan 1, 2014Azienda Ospedaliera San Camillo Forlanini, European Organisation for Research and Treatment of Cancer, Université catholique de Louvain
NCT01866423Phase 2Oct 25, 2013Millennium Pharmaceuticals, National Cancer Institute (NCI), University of Southern California
NCT01816048Phase 2May 1, 2013Millennium Pharmaceuticals, University of Wisconsin
NCT01809691Phase 3Mar 1, 2013Millennium Pharmaceuticals, National Cancer Institute (NCI), Southwest Oncology Group, University of Utah
NCT03211052Phase 2Feb 18, 2013Millennium Pharmaceuticals, University of London
NCT01808040Phase 1Nov 1, 2012Millennium Pharmaceuticals, University of Wisconsin
NCT01707966Phase 3Sep 1, 2012Cantonal Hospital of St. Gallen, Kantonsspital Graubünden, Swiss Group for Clinical Cancer Research
NCT01666314Phase 1/Phase 2 (Phase 2)Sep 1, 2012Millennium Pharmaceuticals
NCT01546987Phase 3May 1, 2012Harvard University, National Cancer Institute (NCI), NRG Oncology, Radiation Therapy Oncology Group
NCT01549951Phase 2May 1, 2012Millennium Pharmaceuticals
NCT01193257Phase 3Nov 1, 2010Millennium Pharmaceuticals
NCT01193244Phase 3Oct 1, 2010Millennium Pharmaceuticals
NCT01084655Phase 1/Phase 2 (Phase 2)Jul 1, 2010Millennium Pharmaceuticals
NCT01046916Phase 2May 1, 2010Millennium Pharmaceuticals
NCT00569153Phase 1/Phase 2 (Phase 2)Apr 1, 2008Millennium Pharmaceuticals
Showing 19 of 19 trials
Page 1 / 1

Organizations

Research & Development (28)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Millennium PharmaceuticalsFor profit14732008
National Cancer Institute (NCI)Government3022012
Cantonal Hospital of St. GallenAcademic/Hospital2012012
Kantonsspital GraubündenAcademic/Hospital2012012
Swiss Group for Clinical Cancer ResearchAcademic/Hospital2212012
University of WisconsinAcademic/Hospital2222012
Azienda Ospedaliera San Camillo ForlaniniAcademic/Hospital1012014
Clinica Universidad de NavarraAcademic/Hospital1012014
European Organisation for Research and Treatment of CancerAcademic/Hospital1112014
Grupo Español de Tumores Huérfanos e InfrecuentesAcademic/Hospital1112014
Harvard UniversityAcademic/Hospital1012012
Hospital Son LlatzerAcademic/Hospital1012014
Hospital Universitario Fundación AlcorcónAcademic/Hospital1012014
Hospital Universitario Madrid SanchinarroAcademic/Hospital1012014
Johns Hopkins UniversityAcademic/Hospital1112014
NRG OncologyAcademic/Hospital1012012
Radiation Therapy Oncology GroupAcademic/Hospital1112012
SCRI Development InnovationsFor profit1112014
Southwest Oncology GroupAcademic/Hospital1112013
TakedaFor profit1012014
28 organizations
Page 1 / 2